Planta Med 2018; 84(06/07): 372-393
DOI: 10.1055/s-0043-123764
Reviews
Georg Thieme Verlag KG Stuttgart · New York

Do We Need Plant Food Supplements? A Critical Examination of Quality, Safety, Efficacy, and Necessity for a New Regulatory Framework

Mona Abdel-Tawab
Central Laboratory of German Pharmacists, Eschborn, Germany
› Author Affiliations
Further Information

Publication History

received 25 August 2017
revised 14 November 2017

accepted 20 November 2017

Publication Date:
08 December 2017 (online)

Abstract

Given the expanding market of plant food supplements (PFSs) not undergoing any pre-marketing authorization, the overall quality, safety and efficacy of PFSs were subjected to a critical examination. Although many high-quality PFSs exist on the legal market, quality concerns are in general justified. Besides economic adulteration, active ingredients dramatically differing from label claims and among products were reported in several studies. In addition, PFSs sold via the Internet may be intentionally adulterated with undeclared prescription drugs. Compared to PFSs with only one single herb, PFSs containing herbal mixtures were more involved in moderate and severe clinical courses. Although prohibited by regulation, misleading labels on PFSs are common. Above all, only vague evidence for the efficacy of PFSs exists. Notwithstanding the unproven efficacy and insufficient safety assessment, PFSs represent a relevant source for consumers to get access to herbal preparations in the United States and meanwhile also in Europe, as launching of licensed/registered European herbal medicinal products (HMPs) has steadily decreased. However, being non-vitamin, non-mineral products, PFSs are neither food nor drugs. In terms of protecting public health and providing the consumer with high-quality, effective, and safe PFSs, possibilities are shown how to deal with the many challenges of PFSs. Last but not least, suggestions are made for assigning PFSs a separate regulatory category being less regulated compared to HMPs but more strictly regulated compared to food laws including implementation of good manufacturing practices and a scientific pre-marketing review process by an expert commission.

 
  • References

  • 1 Biagi M, Pecorari R, Appendino G, Miraldi E, Magnano AR, Governa P, Cettolin G, Giachetti D. Herbal products in Italy: the thin line between phytotherapy, nutrition and paraphamaceuticals; a normative overview of the fastest growing market in Europe. Pharmaceuticals 2016; 9: E65
  • 2 Cranz H, Anquez-Traxler C. TradReg 2013: regulation of herbal and traditional medicinal products-European and global strategies-international symposium. J Ethnopharmacol 2014; 158: 495-497
  • 3 Global Industry Analysts, Inc. Global herbal supplements and remedies market to reach USD$107 billion by 2017, according to new report by Global Industry Analysts, Inc. PRWeb. Available at http://www.prweb.com/releases/herbal_supplements/herbal_remedies/prweb9260421.htm Accessed May 30, 2017
  • 4 Minghetti P, Franzè S, Zaccara V, Raso F, Morazzoni P. Innovation in phytotherapy: is a new regulation the feasible perspective in Europe?. Planta Med 2016; 82: 591-595
  • 5 Council of the European Economic Community. Directive 65/65/EEC, 1965. Council Directive 65/65/EEC of 26. January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products. Official Journal 1965; 22: 369-373 (09.02.1965)
  • 6 Council of the European Economic Community. Directive 87/21/EEC, 1987. Council Directive 87/21/EEC of 22. December 1986 amending Directive 65/65/EEC on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products. Official Journal 1987; 15: 36-37 (17.01.1987)
  • 7 European Parliament, Council of the European Union. Directive 2004/24/EC, 2004. Commission Directive 2004/24/EC of the European Parliament and of the Council of 31. March 2004 amending, as regards traditional herbal medicinal products, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal 2004; 136: 85-90 (30.04.2004)
  • 8 Quintus C, Schweim HG. European regulation of herbal medicinal products on the border area to the food sector. Phytomedicine 2012; 19: 378-381
  • 9 European Medicines Agency. Uptake of the traditional use registration scheme and implementation of the provisions of Directive 2004/24/EC in EU Member States. 2015. Available at. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/05/WC500106706.pdf Accessed December 6, 2017
  • 10 Silano V, Coppens P, Larranaga-Guetaria A, Minghetti P, Roth-Ehrang R. Regulations applicable to plant food supplements and related products in the European Union. Food Funct 2011; 2: 710-719
  • 11 Garcia-Alvarez A, Egan B, de Klein S, Dima L, Maggi FM, Isoniemi M, Ribas-Berba L, Raats MM, Meissner EM, Badea M, Bruno F, Salmenhaara M, Milà-Villarroel R, Knaze V, Hodgkins C, Marculescu A, Uusitalo L, Restani P, Serra-Majem L. Usage of plant food supplements across six European countries: findings from PlantLIBRA consumer survey. PLoS One 2014; 9: e92265
  • 12 Dietary Supplement and nonprescription Drug Consumer Protection Act. Public Law 109 – 462. Washington D.C.: United States Government Printing Office; 2006. Accessed December 4, 2017
  • 13 Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation. J Gen Intern Med 2008; 23: 854-859
  • 14 Jiratchariyakul W, Mahady GB. Overview of botanical status in EU, USA, and Thailand. Evid Based Complement Alternat Med 2013; 2013: 480128
  • 15 Food and Drug Administration. Dietary Supplement Current Good Manufacturing Practices (CGMPs) and Interim Final Rule (IFR) Facts. Available at. https://www.fda.gov/Food/GuidanceRegulation/CGMP/ucm110858.htm Accessed July 17, 2017
  • 16 Pawar RS, Handy SM, Cheng R, Shyong N, Grundel E. Assessment of the authenticity of herbal dietary supplements: comparison of chemical and DNA barcoding methods. Planta Med 2017; 83: 921-936
  • 17 Smith T, Kawa K, Eckl V, Morton C, Stredney R. Herbal supplement sales in US increase 7.7 % in 2016. Consumer preferences shifting toward ingredients with general wellness benefits, driving growth of adaptogens and digestive health products. HerbalGram 2017; 115: 56-65
  • 18 Avigan MI, Mozersky RP, Seeff LB. Scientific and regulatory perspectives in herbal and dietary supplement associated hepatotoxicity in the United States. Int J Mol Sci 2016; 17: 331
  • 19 Lüde S, Vecchio S, Sinno-Tellier S, Dopter A, Mustonen H, Vucinic S, Jonsson B, Müller D, Veras Gimenez Fruchtengarten L, Hruby K, De Souza Nascimento E, Di Lorenzo C, Restani P, Kupferschmidt H, Ceschi A. Adverse effects of plant food supplements and plants consumed as food: results from the poisons centres – based PlantLIBRA study. Phytother Res 2016; 30: 988-996
  • 20 Kennedy J. Herb and supplement use in the US adult population. Clin Ther 2005; 27: 1847-1858
  • 21 Peters CL, Shelton J, Sharma P. An investigation of factors that influence the consumption of dietary supplements. Health Mark Q 2003; 21: 113-135
  • 22 Egan B, Hodgkins C, Shepherd R, Timotijevic L, Raats M. An overview of consumer attitudes and beliefs about plant food supplements. Food Funct 2011; 2: 747-752
  • 23 Brevort P. The booming US botanical market: a new overview. HerbalGram 1998; 44: 33-48
  • 24 Vaclavik L, Krynitsky AJ, Rader JI. Mass spectrometric analysis of pharmaceutical adulterants in products labeled as botanical dietary supplements or herbal remedies: a review. Anal Bioanal Chem 2014; 406: 6767-6790
  • 25 Walker KM, Applequist WL. Adulteration of selected unprocessed botanicals in the U.S. retail herbal trade. Econ Bot 2012; 66: 321-327
  • 26 Kapoor A, Sharfstein JM. Breaking the gridlock: regulation of dietary supplements in the United States. Drug Test Anal 2016; 8: 424-430
  • 27 Booker A, Frommenwiler D, Reich E, Horsfield S, Heinrich M. Adulteration and poor quality of Ginkgo biloba supplements. J Herb Med 2016; 6: 79-87
  • 28 Tawab M, Krzywon M, Schubert-Zsilavecz M. Nahrungsergänzungsmittel mit Ginkgo unter der Lupe. Pharm Ztg 2010; 155: 86-91
  • 29 Avula B, Sagi S, Gafner S, Upton R, Wang YH, Wang M, Khan IA. Identification of Ginkgo biloba supplements adulteration using high performance thin layer chromatography and ultra high performance liquid chromatography-diode array detector-quadrupole time of flight-mass spectrometry. Anal Bioanal Chem 2015; 407: 7733-7746
  • 30 Lee J. Marketplace analysis demonstrates quality control standards needed for black raspberry dietary supplements. Plant Foods Hum Nutr 2014; 69: 161-167
  • 31 Meins J, Artaria C, Riva A, Morazzoni P, Schubert-Zsilavecz M, Abdel-Tawab M. Survey on the quality of the top-selling European and American botanical dietary supplements containing boswellic acids. Planta Med 2016; 82: 573-579
  • 32 Harkey MR, Henderson GL, Gershwin ME, Stern JS, Hackman RM. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr 2001; 73: 1101-1106
  • 33 Khan IM. Issues related to botanicals. Life Sci 2006; 78: 2033-2038
  • 34 Fitzloff J, Yat P, Lu Z, Awang DVC, Amason JT, van Breemen RB, Hall T, Blumenthal M, Fong HHS. Perspectives on the Quality Assurance of Ginseng Products in North America. In: Huh H, Choi KJ, Kim YC. eds. Advances in Ginseng Research: Proceedings of the 7th International Symposium on Ginseng. Seoul: The Korean Society of Ginseng; 1998: 138-145
  • 35 Awang DVC, Yat PN, Amason JT, Lu ZZ, Fitzloff JF, Fong H, Hall T, Blumenthal M. The American Botanical Councilʼs program of evaluation of ‘ginseng’ products on the North American market. International Ginseng Conference 99. Ginseng: its science and its markets. Advances in biotechnology, medicinal apolications and marketing. Hong Kong, China; 1999: abstract. No. A17
  • 36 Constantine GH, Karchesy J. Variations in Hypericin Concentrations in Hypericum perforatum L. and commercial Products. Tunica: American Society of Pharmacognosy Interim Meeting; 1999
  • 37 Rocha T, Amaral JS, Oliviera MBPP. Adulteration of dietary supplements by illegal addition of synthetic drugs: a review. Compr Rev Food Sci Food Saf 2016; 15: 43-62
  • 38 Wang J, Chen B, Yao S. Analysis of six synthetic adulterants in herbal weight-reducing dietary supplements by LC electrospray ionization-MS. Food Addit Contam A 2008; 25: 822-830
  • 39 Carvalho LM, Martini M, Moreira AL, de Lima APS, Correia D, Falcao T, Garcia SC, de Bairros AV, do Nascimento PC, Bohrer D. Presence of synthetic pharmaceuticals as adulterants in slimming phytotherapeutic formulations and their analytical determination. Forensic Sci Int 2011; 204: 6-12
  • 40 Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin dependent diabetes. Obes Res 1998; 6: 47-53
  • 41 Deventer K, van Thuine W, Mikulcikova P, Van Ecnoo P, Delbeke FT. Detection of selected stimulants as contaminants in solid nutritional supplements by liquid chromatography-mass spectrometry. Food Chem 2007; 103: 1508-1513
  • 42 Pawar RS, Grundel E, Fardin-Kia AR, Rader JI. Determination of selected biogenic amines in Acacia rigidula plant materials and dietary supplements using LC-MS/MS method. J Pharm Biomed Anal 2014; 88: 457-466
  • 43 Cohen PA, Venhuis BJ. Adulterated sexual enhancement supplements: more than mojo. JAMA Inter Med 2013; 173: 1169-1170
  • 44 Venhuis BJ, de Kaste D. Towards a decade of detecting new analogues of sildenafil, tadalafil and vardenafil in food supplements. J Pharm Biomed Anal 2012; 69: 196-208
  • 45 Bogusz MJ, Hassan H, Al-Enazi E, Ibrahim Z, Al-Tufail M. Application of LC-ESI-MS-MS for detection of synthetic adulterants in herbal remedies. J Pharm Biomed Anal 2006; 41: 554-564
  • 46 Wang J, Yang D, Wang Z, Chen B, Yao S. Simultaneous determination of illegal additives in dietary supplements and traditional medicines by high performance liquid-chromatography-electrospray ionization mass spectrometry. Chromatographia 2009; 70: 1353-1359
  • 47 Lu YL, Zhou NL, Liao SY, Su N, He DX, Tian QQ, Chen B, Yao SZ. Detection of adulteration of anti-hypertension dietary supplements and traditional Chinese medicines with synthetic drugs using LC/MS. Food Addit Contam A 2010; 27: 893-902
  • 48 Kim HJ, Lee JH, Part HJ, Kim JY, Cho S, Kim WS. Determination of non-opioid analgesics in adulterated food and dietary supplements by LC-MS/MS. Food Addit Contam A 2014; 31: 973-978
  • 49 Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol 2014; 4: 177
  • 50 Heinrich M. Quality and safety of herbal medical products: regulation and the need for quality assurance along the value chain. Br J Clin Pharmacol 2015; 80: 62-66
  • 51 European Food Safety Authority. Guidance on safety assessment of botanicals and botanical preparations intended for use as ingredients in food supplements. 2009. Available at. http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2009.1249/epdf Accessed July 28, 2017
  • 52 Nicoletti M. Nutraceuticals and botanicals: overview and perspectives. Int J Food Sci Nutr 2012; 63 (Suppl. 01) 2-6
  • 53 Di Lorenzo C, Ceschi A, Kupferschmidt H, Lüde S, De Souza Nascimento E, Dos Santos A, Colombo F, Frigerio G, Nørby K, Plumb J, Finglas P, Restani P. Adverse effects of plant food supplements and botanical preparations: a systematic review with critical evaluation of causality. Br J Clin Pharmacol 2015; 79: 578-592
  • 54 Mowry JB, Spyker DA, Cantilena jr. LR, McMillan N, Ford M. 2013 annual report of the American Association of Poison Control Centersʼ national poison data system (NPDS): 31st annual report. Clin Toxicol (Phila) 2014; 52: 1032-1283
  • 55 Haller CA, Kearney T, Bent S, Ko R, Benowitz NL, Olson K. Dietary supplement adverse events: report of a one-year poison center surveillance project. JMT 2008; 4: 84-92
  • 56 Bucchini L, Rodarte A, Restani P. The PlantLIBRA project: how we intend to innovate the science of botanicals. Food Funct 2011; 2: 769-773
  • 57 Menniti-Ippolito F, Mazzanti G, Santucio C, Moro PA, Calapai G, Firenzuoli F, Valeri A, Raschetti R. Surveillance of suspected adverse reactions to natural health products in Italy. Pharmacoepidemiol Drug Saf 2008; 17: 626-635
  • 58 Taibi DM, Landis CA, Petry H, Vitiello MV. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev 2007; 11: 209-230
  • 59 Isbrucker RA, Burdock GA. Risk and safety assessment on the consumption of licorice root (Glycyrrhiza sp.) its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul Toxicol Pharmacol 2006; 46: 167-192
  • 60 Leitolf H, Dixit KCS, Higham CE, Brabant G. Licorice – or more?. Exp Clin Endocrinol Diabetes 2010; 118: 250-253
  • 61 Mazzanti G, Di Sotto A, Vitalone A. Hepatotoxicity of green tea: an update. Arch Toxicol 2015; 89: 1175-1191
  • 62 Gloro R, Hourmand-Ollivier I, Mosquet B, Mosquet L, Rousselot P, Salamé E, Piquet MA, Dao T. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol 2005; 17: 1135-1137
  • 63 Vial T, Bernard G, Lewden B, Dumortier J, Descotes J. [Acute hepatitis due to Exolise, a Camellia sinensis-derived drug]. Gastroenterol Clin Biol 2003; 27: 1166-1167
  • 64 Lynch CR, Folkers ME, Hutson WR. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transpl 2006; 12: 989-992
  • 65 Vannaci A, lapi F, Gallo E, Vietri M, Toti M, Menniti-Ippolito F, Raschette R, Firenzuoli F, Mugelli A. A case of hepatitis associated with long-term use of Cimicifuga racemosa . Altern Ther Health Med 2009; 15: 62-63
  • 66 Zimmermann R, Witte A, Voll RE, Strobel J, Frieser M. Coagulation activation and fluid retention associated with the use of black cohosh: a case study. Climacteric 2010; 13: 187-191
  • 67 Minicullo PL, Saija A, Patafi M, Marotta G, Ferlazzpo B, Gangemi S. Muscle damage induced by black cohosh (Cimicifuga racemosa). Phytomedicine 2006; 13: 115-118
  • 68 Ingraffea A, Donohue K, Wilkel C, Falanga V. Cutaneous vasculitis in two patients taking an herbal supplement containing black cohosh. J Am Acad Deratol 2007; 56: S124-S126
  • 69 Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatotoxicity. Med J Aust 2002; 177: 440-443
  • 70 Meyer S, Vogt T, Obermann EC, Landthaler M, Karrer S. Cutaneous pseudolymphoma induced by Cimicifuga racemosa . Dermatology 2007; 214: 94-96
  • 71 Svedlund E, Larsson M, Hägerkvist R. Spontaneously reported adverse reactions for herbal medicinal products and natural remedies in Sweden 2007–15: report from the Medicinal Products Agency. Drugs Real World Outcomes 2017; 4: 119-125
  • 72 European Medicines Agency. European Community on Cimicifuga racemosa (L.) Nutt., rhizoma (EM/HMPC/600717/2007 Corr.1 ). Available at. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_Community_herbal_monograph/2011/01/WC500100981.pdf Accessed August 4, 2017
  • 73 European Medicines Agency. Assessment report on Cimicifuga racemosa (L.) Nutt., rhizome (EMA/HMPC/3968/2008). Available at. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2011/05/WC500106358.pdf Accessed August 4, 2017
  • 74 Vitalone A, Menniti-Ippolito F, Moro PA, Firenzuoli F, Raschetti R, Mazzanti G. Suspected adverse reactions associated with herbal products used for weight loss: a case series reported to the Italian national Institute of Health. Eur J Clin Pharmacol 2011; 67: 215-224
  • 75 Sultan S, Spector J, Michell RM. Ischemic colitis associated with use of bitter-orange-containing dietary weight-loss supplement. Mayo Clin Proc 2006; 81: 1630-1631
  • 76 Haller CA, Benowitz NL, Jacob 3rd P. Hemodynamic effects of ephedra-free weight loss supplements in humans. Am J Med 2005; 118: 998-1003
  • 77 Speijers G, Bottex B, Dusemund B, Lugasi A, Tóth J, Amberg-Müller J, Galli CL, Silano V, Rietjens IM. Safety assessment of botanicals and botanical preparations used as ingredients in food supplements: testing an European Food Safety Authority-tiered approach. Mol Nutr Food Res 2010; 54: 175-185
  • 78 Van den Berg SJPL, Serra-Majem L, Coppens P, Rietjens IM. Safety assessment of PFS. Food Funct 2011; 2: 760-768
  • 79 Rietjens IM, Martena MJ, Boersma MG, Spiegelenberg W, Alink GM. Molecular mechanism of toxicity of important food-borne pyhtotoxins. Mol Nutr Food Res 2005; 49: 131-158
  • 80 Noel JC, Anaf V, Fayt I, Wespes E. Ureteral mullerian carcinosarcoma (mixed mullerian tumor) associated with endometriosis occurring in a patient with a concentrated soy isoflavones supplementation. Arch Gynecol Obstet 2006; 274: 389-392
  • 81 Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, Walker M, Humphrey L. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295: 2057-2071
  • 82 Wolters M, Hahn A. Soy isoflavones – a therapy for menopausal symptoms?. Wien Med Wochenschr 2004; 154: 334-341
  • 83 Fritz H, Seely D, Flower G, Skidmore B, Fernandes R, Vadeboncoeur S, Kennedy D, Cooley K, Wong R, Sagar S, Sabri E, Fergusson D. Soy, red clover, and isoflavones and breast cancer: a systematic review. PLoS One 2013; 8: e81968
  • 84 Wu CH, Wang CC, Kennedy J. Changes in herb and dietary supplement use in the US adult population: a comparison of the 2002 and 2007. Clin Ther 2011; 33: 1749-1758
  • 85 Van der Voet GB, Sarafonov A, Todorov TI, Centeno JA, Jonas WB, Ives JA, Mullick FG. Clinical and analytic toxicology of dietary supplements: a case study and review of the literature. Biol Trace Element Res 2008; 125: 1-12
  • 86 Stickel F, Droz S, Patsenker E, Bögli-Stuber K, Aebi B, Leib SL. Severe hepatotoxicity following ingestion of Herbalife contaminated with Bacillus subtilis . J Hepatol 2009; 50: 111-117
  • 87 Veprikova Z, Zachariasova M, Dzuman Z, Zachariasova A, Fenclova M, Slavikova P, Vaclavikova M, Mastovska K, Hengst D, Hajslova J. Mycotoxins in plant-based dietary supplements: hidden health risk for consumers. J Agric Food Chem 2015; 63: 6633-6643
  • 88 Schulz M, Meins J, Diemert S, Zagermann-Muncke P, Goebel R, Schrenk D, Schubert-Zsilavecz M, Abdel-Tawab M. Detection of pyrrolizidine alkaloids in German licensed herbal medicinal teas. Phytomedicine 2015; 22: 648-656
  • 89 Medicines and Healthcare Products Regulatory Agency. Precautionary recall – six batches of St. Johnʼs wort tablets. Available at. https://www.gov.uk/government/news/precautionary-recall-six-batches-of-st-johns-wort-tablets Accessed August 7, 2017
  • 90 Mathon C, Ankli A, Reich E, Bieri S, Christen P. Screening and determination of sibutramine in adulterated herbal slimming supplements by HPTLC-UV densitometry. J Chromatogr B Anal Technol Biomed Life Sci 2014; 967: 174-182
  • 91 da Justa Neves DB, Caldas ED. Dietary supplements: international legal framework and adulteration profiles, and characteristics of products on the Brazilian clandestine market. Regul Toxicol Pharmacol 2015; 73: 93-104
  • 92 Geller AI, Shehab N, Weidle NJ, Maribeth C, Lovegrove MPH, Wolpert BJ, Babgaleh B, Timbo MD, Mozersky RP, Budnitz DS. Emergency department visits for adverse events related to dietary supplements. N Engl J Med 2015; 373: 1531-1540
  • 93 Reeuwijk NM, Venhuis BJ, de Kaste D, Hoogenboom LA, Rietjens IM, Martena MJ. Sildenafil and analogous phosphodiesterase type 5 (PDE-5) inhibitors in herbal food supplements sampled on the Dutch market. Food Addit Contam A Chem Anal Control Expo Risk Assess 2013; 30: 2027-2034
  • 94 Damiano F, Silva C, Gregori A, Vacondio F, Mor M, Menozzi M, Di Giorgio D. Analysis of illicit dietary supplements sold in the Italian market: identification of a sildenafil thioderivative as adulterant using UPLC-TOF/MS and GC/MS. Sci Justice 2014; 54: 228-237
  • 95 Sarma N, Giancaspro G, Venema J. Dietary supplements quality analysis tools from the United States Pharmacopeia. Drug Test Anal 2016; 8: 418-423
  • 96 Cohen PA, Maller G, DeSouza R, Neal-Kaback J. Presence of banned drugs in dietary supplements following FDA recalls. JAMA 2014; 312: 1691-1693
  • 97 Sprouse AA, van Breemen R. Pharmacokinetic interactions between drugs and botanical dietary supplements. Drug Met Dispos 2016; 44: 162-171
  • 98 Tirona RG, Bailey DG. Herbal product-drug interactions mediated by induction. Br J Clin Pharmacol 2006; 61: 677-681
  • 99 Hall SD, Wang Z, Huang SM, Hamman MA, Vasaveda N, Adigum AQ, Hilligoss JK, Miller M, Gorski JC. The interaction between St. Johnʼs wort and an oral contraceptive. Clin Pharmacol Ther 2003; 74: 525-535
  • 100 Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St. Johnʼs wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 57: 592-599
  • 101 Raynor DK, Dickinson R, Knapp P, Long AF, Nicolson DJ. Buyer beware? Does the information provided with herbal products available over the counter enable safe use?. BMC Med 2011; 9: 94
  • 102 Clauson KA, Santamarina ML, Rutledge JC. Clinically relevant safety issues associated with St. Johnʼs wort product labels. BMC Complement Altern Med 2008; 8: 42
  • 103 Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C, Mastrangelo S. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 2009; 65: 331-341
  • 104 Anderson GD, Rosito G, Mohustsy MA, Elmer GW. Drug interaction potential of soy extract and Panax ginseng . J Clin Pharmacol 2003; 43: 643-648
  • 105 Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, E. purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6 and 2C9. J Altern Complement Med 2005; 11: 433-439
  • 106 Ohnishi N, Kusuhara M, Yoshioka M, Kuroda K, Soga A, Nishikawa F, Koishi T, Nakagawa M, Hori S, Matsumoto T, Yamashita M, Ohta S, Takara K, Yokoyama T. Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. Biol Pharm Bull 2003; 26: 1315-1320
  • 107 Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002; 72: 276-287
  • 108 Tsai HH, Lin HW, Pickard AW, Tsai HY, Mahady GB. Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. Int J Clin Pract 2012; 66: 1056-1078
  • 109 Vitry AI. Comparative assessment of four drug interactions compendia. Br J Clin Pharmacol 2007; 63: 709-714
  • 110 Bent S, Ko R. Commonly used herbal medicines in the United States: a review. Am J Med 2004; 116: 478-485
  • 111 Izzo AA, Hoon-Kim S, Radhakrishan R, Williamson EM. A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies. Phythother Res 2016; 30: 691-700
  • 112 Ried K, Toben C, Fakler P. Effect of garlic on serum lipids: an updated meta-analysis. Nutr Rev 2013; 71: 282-299
  • 113 Alali FQ, El-Eimat T, Khalid L, Hudaib R, Al-Shehabi TS, Eid AH. Garlic for cardiovascular disease: prevention or treatment. Curr Pharm Des 2017; 23: 1028-1041
  • 114 Alkanjari O, Vitalone A. What do we know about phytotherapy of benign prostatic hyperplasia?. Life Sci 2015; 126: 42-56
  • 115 Ooi SL, Pak SC. Serenoa repens for lower urinary tract symptoms/benign prostatic hyperplasia: current evidence and its clinical implications in naturopathic medicine. J Altern Complement Med 2017; 23: 599-606
  • 116 Russo A, Capgrosso P, La Croce G, Ventimiglia E, Boeri L, Briganti A, Damiano R, Montorsi F, Salonia A. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia. Expert Opin Drug Saf 2016; 15: 1661-1670
  • 117 Novara G, Giannarini G, Alcaraz A, Cózar-Olmo JM, Descazeaud A, Montorsi F, Ficarra V. Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized clinical trials. Eur Urol Focus 2016; 2: 553-561
  • 118 De Smet P. Herbal remedies. NEJM 2002; 347: 2046-2056
  • 119 Karsch-Völk M, Barrett B, Linde K. Echinacea for preventing and treating the common cold. JAMA 2015; 13: 618-619
  • 120 Giles JT, Palat 3rd CT, Chien SH, Chang ZG, Kennedy DT. Evaluation of Echinacea for treatment of the common cold. Pharmacotherapy 2000; 20: 690-697
  • 121 Lee NH, Son CG. Systematic review of randomized controlled trials evaluating the efficacy and safety of ginseng. J Acupunct Meridian Stud 2011; 4: 85-89
  • 122 Niedzwiecki A, Roomi MW, Kalinovsky T, Rath M. Anticancer efficacy of polyphenols and their combinations. Nutrients 2016; 8: E552
  • 123 Sinha D, Biswas J, Nabavi SM, Bishayee A. Tea phytochemicals for breast cancer prevention and intervention: from bench to bedside and beyond. Semin Cancer Biol 2017; 46: 33-54
  • 124 Dietz BM, Hajirahimkhan A, Dunlap TL, Bolton JL. Botanicals and their bioactive phytochemicals for womenʼs health. Pharmacol Rev 2016; 68: 1026-1073
  • 125 Tanmahasamut P, Vichinsartvichai P, Rattanachaiyanont M, Techatraisak K, Dangrat C, Sardod P. Cimicifuga racemosa extract for relieving menopausal symptoms: a randomized controlled trial. Climacteric 2015; 18: 79-85
  • 126 North American Menopause Society. The role of soy isoflavones in menopausal health: report of the North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). Menopause 2011; 18: 732-753
  • 127 Bolaños R, Del Castillo A, Francia J. Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis. Menopause 2010; 17: 660-666
  • 128 Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev 2013; (12) CD001395
  • 129 Morris CA, Avorn J. Internet marketing of herbal products. JAMA 2003; 290: 1505-1509
  • 130 US Government Accountability Office. Herbal dietary supplements: examples of deceptive or questionable marketing practices and potentially dangerous advice. Available at. http://www.gao.gov/products/GAO-10-662 Accessed August 7, 2017
  • 131 Fransen HP, Pelgrom SMGJ, Stewart-Knox B, de Kaste D, Verhagen H. Assessment of health claims, content, and safety of herbal supplements containing Ginkgo biloba . Food Nutr Res 2010; 54: 5221
  • 132 Miracleburn with Hoodia and patented Advantra-Z. Available at. http://www.4diamaxol.com/miracleburn.htm Accessed August 9, 2017
  • 133 Stickel F, Shouval D. Hepatotoxicity of herbal and dietary supplements: an update. Arch Toxicol 2015; 89: 851-865
  • 134 Cardellina 2nd JH. Challenges and opportunities confronting the botanical dietary supplement industry. J Nat Prod 2002; 65: 1073-1084
  • 135 van Breemen RB. Development of safe and effective botanical dietary supplements. J Med Chem 2015; 58: 8360-8372
  • 136 Markowitz JS, Zhu HJ. Limitations of in vitro assessments of the drug interaction potential of botanical supplements. Planta Med 2012; 78: 1421-1427
  • 137 Chen ML, Straughn AB, Sadrieh N, Meyer M, Faustino PJ, Ciavarella AB, Meibohm B, Yates CR, Hussain AS. A modern view of excipient effects on bioequivalence: case study of sorbitol. Pharm Res 2007; 24: 73-80
  • 138 Markowitz JS, von Moltke LL, Donovan JL. Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations. Mol Nutr Food Res 2008; 52: 747-754
  • 139 Teschke R, Bahre R, Genthner A, Fuchs J, Schmidt-Taenzer W, Wolff A. Suspected black cohosh hepatotoxicity – challenges and pitfalls of causality assessment. Maturitas 2009; 63: 302-304
  • 140 Teschke R, Schulze J, Schwarzenboeck A, Eickhoff A, Frenzel C. Herbal hepatotoxicity: suspected cases assessed for alternative causes. Eur J Gastroenterol Hepatol 2013; 25: 1093-1098
  • 141 Zheng XX, Xu YL, Li SH, Hui R, Wu YJ, Huang XH. Effects of green tea catechins with or without caffeine on glycemic control in adults: a metaanalysis of randomized controlled trials. Am J Clin Nutr 2013; 97: 750-762
  • 142 Nahrstedt A, Butterweck V. Lessons learned from herbal medicinal products: the example of St. Johnʼs wort. J Nat Prod 2010; 73: 1015-1021
  • 143 Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet 2011; 50: 349-369
  • 144 Nieman DC, Shanely RA, Luo B, Dew D, Meaney MB, Sha W. A commercialized dietary supplement alleviates joint pain in community adults: a double-blind, placebo-controlled community trial. Nutr J 2013; 12: 154
  • 145 Du Z, Liu Z, Ning Z, Liu Y, Song Z, Wang C, Lu A. Prospects of boswellic acids as potential pharmaceutics. Planta Med 2015; 81: 259-271
  • 146 Di Lorenzo C, DellʼAgli M, Badea M, Dima L, Colombo E, Sangiovanni E, Restani P, Bosisio E. Plant food supplements with anti-inflammatory properties: a systematic review (II). Crit Rev Food Sci Nutr 2013; 53: 507-516
  • 147 Ernst E. Frankincense: systematic review. BMJ 2008; 337: 1-4
  • 148 Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013; 15: 195-218
  • 149 Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res 2014; 58: 516-527
  • 150 European Food Safety Authority. “General function” health claims under Article 13. Available at. http://www.efsa.europa.eu/en/ndaclaims/ndaclaims13.htm Accessed August 16, 2017
  • 151 Kuszak AJ, Hopp DC, Williamson JS, Betz JM, Sorkin BC. Approaches by the US National Institutes of Health to support rigorous scientific research on dietary supplements and natural products. Drug Test Anal 2016; 8: 413-417
  • 152 Jacobs BP, Bent S, Tice JA, Blackwell T, Cummings SR. An Internet based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine (Baltimore) 2005; 84: 197-207
  • 153 U.S. Food Drug Administration. Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims-Final. Washington, D.C.: U.S. Food Drug Administration; 2009. Available. at https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/LabelingNutrition/ucm073332.htm Accessed. August. 18. 2017
  • 154 Finley JW, Finley JW, Ellwood K, Hoadley J. Launching a new product or dietary supplement in the United States: industrial, regulatory, and nutritional considerations. Annu Rev Nutr 2014; 34: 421-447
  • 155 Costello RB, Coates P. In the midst of confusion lies opportunity: fostering quality science in dietary supplement research. J Am Coll Nutr 2001; 20: 21-25
  • 156 Wilson T, Bauer BA. Advising consumers about dietary supplements: lessons from cranberry products. J Diet Suppl 2009; 6: 377-384